Healthcare & Life Sciences
Lyell Immunopharma
United Stateswww.lyell.com
Lyell Immunopharma is a series c plus startup based in United States. 1 investor tracked. Status: ipo.
IPOseries-c-plus
series-c-plus
Stage
2017
Founded
3
Investors
About Lyell Immunopharma
Based in the United States, Lyell Immunopharma is a startup founded in 2017. Its most recent tracked round is Series C+. Brouky classifies it under Healthcare & Life Sciences. Brouky records 3 investors associated with the company.
Lyell Immunopharma develops engineered cell therapies aimed at improving cancer treatment by overcoming barriers in the tumor microenvironment to enhance T cell therapies.
Explore Lyell Immunopharma's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.